-
骨骼系统作为人体的支柱,具有非常重要的生理作用。其病变可由许多因素造成,如肿瘤、外伤、炎症和代谢性骨病等[1]。检查这些疾病的影像学方法有X射线、CT、MRI和超声等,SPECT骨骼显像与X射线影像不同,除了能显示骨骼的主要解剖结构外,还能反映局部骨骼的血流变化、盐代谢和成骨细胞活性等,因此较X射线能更早地发现骨骼病变,并可进行全身显像,在骨骼病变的诊断中具有早期诊断和全身扫描的优势[2]。全身骨骼显像是我国当前SPECT最主要的临床应用,据最近几次由中华医学会核医学分会发起的普查统计,SPECT全身骨骼显像年检查病例在100万例以上,占全部临床应用的50%~60%[3]。NET 632型SPECT是北京永新医疗设备有限公司自主研发的国内首台可变角双探头SPECT,其在全身骨骼显像应用上研制开发了NovelSharp快速采集算法,为验证NET 632型SPECT在全身骨骼显像中的病灶识别及图像质量情况,本研究将其与德国西门子公司的同类产品Symbia T16型SPECT/CT显像的图像进行对比研究。
NET632型SPECT与Symbia T16型SPECT/CT在全身骨骼显像中的图像对比
Comparing the NET632 SPECT and the Symbia T16 SPECT/CT images in whole-body bone scintigraphy
-
摘要:
目的 研究北京永新医疗设备有限公司的NET632型SPECT与德国西门子公司的Symbia T16型SPECT/CT在全身骨骼显像中的等效性。 方法 选取2018年3月至9月于内蒙古医科大学附属医院行Symbia T16型SPECT/CT全身骨骼显像结果为阳性病灶的患者32例,其中男性21例、女性11例,年龄(60.87±12.25)岁。32例患者均使用NET632型SPECT行全身骨骼显像。将两种仪器的显像图像采用图像评分标准进行评分,比较阳性病灶累及区域和病灶数量。 结果 Symbia T16型SPECT/CT的图像质量评分为5分的患者有18例、4分的有14例,无3分及以下的患者;NET632型SPECT的图像质量评分为5分的患者有16例、4分的有16例,无3分及以下的患者。Symbia T16型SPECT/CT全身骨显像共发现阳性病灶累及区域数为84个,累及部位为胸部、脊柱、骨盆、四肢和颅骨,病灶数量分别为19、24、20、16、5个;NET632型SPECT在相同位置发现与其数目相等的病灶。 结论 永新医疗的NET632型SPECT与西门子公司的Symbia T16型SPECT/CT在全身骨骼显像探测病灶方面具有等效性。 -
关键词:
- 单光子发射计算机体层摄像术 /
- 体层摄影术,发射型计算机,单光子 /
- 全身骨骼显像 /
- 西门子Symbia T16型 /
- 永新医疗NET632型
Abstract:Objective To study the equivalence of the Novel Medical NET632 SPECT and the SIEMENS Symbia T16 SPECT/CT in whole-body bone scintigraphy. Methods A total of 32 cases (21 males and 11 females; aged 60.87±12.25 years) in the Department of Nuclear Medicine of the Affiliated Hospital of Inner Mongolia Medical University from March 2018 to September 2018 were found positive with bone lesions in the whole-body bone scintigraphy using the SIEMENS Symbia T16 SPECT/CT and the Novel Medical NET632 SPECT. Then, the image quality was compared using the same image scoring criteria. The positive lesion involvement area and the number of areas in each patient were determined using the two devices. Results The image qualities were scored 5, 4, and 3 (including < 3) for 18, 14, and 0 in the Symbia T16 SPECT/CT, and the image qualities were scored 5, 4, and 3(including < 3)for 16, 16, and 0. A total of 84 positive lesion sites were found in the chest, spine, pelvis, limbs, and skull by using the Symbia T16 SPECT/CT, and the numbers in each location were 19, 24, 20, 16, and 5, respectively. The same number of positive lesions was observed in the same locations for the NET 632 SPECT. Conclusion The Novel Medical NET632 SPECT and the SIEMENS Symbia T16 SPECT/CT detect the lesions in whole-body bone scintigraphy equivalently. -
-
[1] 李亚明. 核医学教程[M]. 3版. 北京: 科学出版社, 2014: 179.
Li YM. Nuclear medicine course[M]. 3rd ed. Beijing: Science Press, 2014: 179.[2] 许守林, 冯雪风. 99mTc-MDP骨扫描在乳腺癌骨转移诊断中的应用[J]. 山东医药, 2015, 55(11): 14−17. DOI: 10.3969/j.issn.1002−266X.2016.11.005.
Xu SL, Feng XF. Application of 99mTc-MDP bone scanning in diagnosis of breast cancer with bone metastasis[J]. Shandong Med J, 2015, 55(11): 14−17. DOI: 10.3969/j.issn.1002−266X.2016.11.005.[3] 中华医学会核医学分会. 2016年全国核医学现状普查结果简报[J]. 中华核医学与分子影像杂志, 2016, 36(5): 479−480. DOI: 10.3760/cma.j.issn.2095−2848.2016.05.024.
Chinese Society of Nuclear Medicine. A brief report on the results of the national survey of nuclear medicine in 2016[J]. Chin J Nucl Med Mol Imaging, 2016, 36(5): 479−480. DOI: 10.3760/cma.j.issn.2095−2848.2016.05.024.[4] 丁月云, 石德道, 朱宗平, 等. SPECT/CT骨断层融合显像对肿瘤骨转移诊断价值的探究[J]. 医学影像学杂志, 2017, 27(3): 527−530.
Ding YY, Shi DD, Zhu ZP, et al. The diagnostic value of SPECT/CT bone fusion imaging in detection of malignant bone metastases[J]. J Med Imaging, 2017, 27(3): 527−530.[5] 王东, 孟宪平, 陈则君, 等. SPECT/CT融合图像与全身骨显像对骨转移瘤诊断的价值分析[J]. 中国CT和MRI杂志, 2016, 14(4): 126−129. DOI: 10.3969/j.issn.1672−5131.2016.04.038.
Wang D, Meng XP, Chen ZJ, et al. The Diagnosis Value Analysis of SPECT/CT Fusion Images and Whole Body Bone Imaging for Bone Metastases[J]. Chin J CT MRI, 2016, 14(4): 126−129. DOI: 10.3969/j.issn.1672−5131.2016.04.038.[6] Wilson MA, Calhoun FW. The Distribution of Skeletal Metastases in Breast and Pulmonary Cancer: Concise Communication[J]. J Nucl Med, 1981, 22(7): 594−597. [7] 汤辉, 苏新辉, 张红, 等. SPECT/CT骨显像在肿瘤骨转移患者中的应用观察[J]. 临床医学, 2017, 37(5): 26−28. DOI: 10.19528/j.issn.1003−3548.2017.05.11.
Tang H, Su XH, Zhang H, et al. Application of bone imaging with SPECT/CT in patients with bone metastases[J]. Clin Med, 2017, 37(5): 26−28. DOI: 10.19528/j.issn.1003−3548.2017.05.11.[8] Hakimi A, Jalilian AR, Shirvani-Arani S, et al. Production, quality control, biological evaluation and biodistribution modeling of Lutetium-177 maltolate as a viable bone pain palliative in skeletal metastasis[J]. J Radioanal Nucl Chem, 2015, 303(1): 1−10. DOI: 10.1007/s10967−014−3603−2. [9] 李云波, 何伟, 郭坤, 等. 18F-FDG PET/CT与99Tcm-MDP骨显像在恶性肿瘤骨转移中的检查效能比较[J]. 现代肿瘤医学, 2018, 26(2): 251−256. DOI: 10.3969/j.issn.1672−4992.2018.02.024.
Li YB, He W, Guo K, et al. The comparative study of 18F-FDG PET/CT and 99Tcm-MDP bone scintigraphy in detecting bone metastasis[J]. Mod Oncol, 2018, 26(2): 251−256. DOI: 10.3969/j.issn.1672−4992.2018.02.024.[10] 王云雅, 李桂玉, 王喆, 等. 全身骨显像图像质量常见影响因素分析[J]. 现代肿瘤医学, 2015, 23(3): 406−408. DOI: 10.3969/j.issn.1672−4992.2015.03.34.
Wang YY, Li GY, Wang Z, et al. Analysis of influence factors for quality of whole-body bone scan imaging[J]. Mod Oncol, 2015, 23(3): 406−408. DOI: 10.3969/j.issn.1672−4992.2015.03.34.[11] 姚树林, 窦寰宇, 王新强, 等. 2种SPECT联合质量控制与等效性比较[J]. 医疗卫生装备, 2017, 38(8): 75−78, 90. DOI: 10.7687/j.issn1003−8868.2017.08.075.
Yao SL, Dou HY, Wang XQ, et al. Comparison of joint quality control and equivalence between two SPECT machines[J]. Chin Med Equip J, 2017, 38(8): 75−78, 90. DOI: 10.7687/j.issn1003−8868.2017.08.075.[12] 赵海东, 战雷, 安然, 等. SPECT/CT融合骨显像与常规骨扫描在肿瘤骨转移诊断的对比[J]. 临床医药文献杂志, 2016, 3(50): 9989−9990. DOI: 10.3877/j.issn.2095−8242.2016.50.095.
Zhao HD, Zhan L, An R, et al. Compared the SPECT/CT fusion bone imaging with conventional bone scanning in the diagnosis of tumor bone metastasis[J]. J Clin Med, 2016, 3(50): 9989−9990. DOI: 10.3877/j.issn.2095−8242.2016.50.095.[13] Al-Faham Z, Rydberg JN, Oliver Wong CY. Use of SPECT/CT with 99mTc-MDP Bone Scintigraphy to Diagnose Sacral Insufficiency Fracture[J]. J Nucl Med Technol, 2014, 42(3): 240−241. DOI: 10.2967/jnmt.114.137547.